


## Diagnosis & staging

**2,334**

people were diagnosed with lung cancer in 2023



**34%** of patients were diagnosed at **stage 1/2**  
30% in 2022, 24% in 2021 & 27% in 2020

**45%** of patients presented **with stage 4 lung cancer**  
47% in 2022, 50% in 2021 & 49% in 2020

**27%** of patients were diagnosed **after emergency admission**  
29% in 2022, 24% in 2021 & 28% in 2020

## Waiting times in NSCLC

**97** days

Median time from referral to **surgery** in NSCLC stage 1/2

**78** days

Median time from referral to **SACT** in NSCLC stage 3B-4



## Treatment allocation

### Treatment with curative intent for Non-Small Cell Lung Cancer (NSCLC)

**77%** of patients with NSCLC (stage 1/2, Performance Status (PS) 0-2) received treatment with curative intent\*



\*surgery or radical radiotherapy

**≥80%**



Audit standard

76% in 2022  
67% in 2021  
68% in 2020

**67%** of patients with NSCLC (stage 3A, PS 0-2) received treatment with curative intent\*\*




\*\*surgery, radical radiotherapy or multimodal treatment

**N/A**

61% in 2022  
61% in 2021  
48% in 2020

### Surgery for Non-Small Cell Lung Cancer (NSCLC)

**18%** of patients with NSCLC had surgical treatment for their cancer



**≥17%**



Audit standard

14% in 2022  
13% in 2021  
11% in 2020

### Systemic Anti-Cancer Therapy (SACT) for Non-Small Cell Lung Cancer (NSCLC)

**55%** of patients with NSCLC (stage 3B - 4, PS 0-1) received SACT



**≥70%**




Audit standard

60% in 2022  
57% in 2021  
53% in 2020

### Systemic Anti-Cancer Therapy (SACT) for Small Cell Lung Cancer (SCLC)

**65%** of patients with SCLC received treatment with SACT



**≥70%**



Audit standard

71% in 2022  
71% in 2021  
58% in 2020

Median time from 'decision to treat' to start SACT: 15 days

### Survival outcomes

2,334 patients were diagnosed between 1 January and 31 December 2023. For these patients:

#### Median survival

**301** days  
↑

262 days in 2022  
222 days in 2021  
224 days in 2020

#### One year survival

**46%** ↑

43% in 2022  
39% in 2021  
40% in 2020

## Data quality

### Completeness of key routine data items\*\*\*

\*\*\*information on smoking status unavailable

#### Stage

**99%** **90%**  
Audit standard

#### Performance status

**100%** **90%**  
Audit standard

#### Basis of diagnosis

**100%** **90%**  
Audit standard

#### Morphology

**69%** **75%**  
Audit standard

#### Lung Clinical Nurse Specialist at diagnosis

**98%** **90%**  
Audit standard